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fractures following radiotherapy for long bone
metastases using CT scan-based virtual
simulation: a retrospective study
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and Michel Lapeyre3Abstract
Background: Radiotherapy for long bone metastases (RTLB) can be complicated by fractures, which considerably
increase morbidity and mortality. The aim of this study was to analyze the risk factors for impending fractures
following radiotherapy for long bone metastases (RTLB) using CT scan-based virtual simulation.
Methods: Forty-seven (47) patients were treated with RTLB (18 lung, 11 breast, 10 prostate and 8 other cancers) for
a period of 18 months. Two doctors analyzed the CT images prior to radiation therapy. The impending fractures
were then monitored and the correlation between bone scan parameters and fracture occurrence was analyzed.
Results: The male gender ratio was 0.57 and the mean age 62.8 (33–93) years. The average size of the metastatic
lesions was 32 (8–87) x 2 (6–81) x 52 (7–408) mm with cortical involvement (CI) in 66% of cases. The site was in the
upper third of the bone in 92% of cases (28 femoral, 17 humeral and two tibial).
Ten fractures occurred: two during RTLB, seven after one month and one after 6.6 months. The fractured lesions
measured 48 (17–87) x 34 (12–66) x 76 (38–408) mm. The predictive parameters for fracture were osteolytic (39% vs.
10%; p = 0.02) and permeative lesions (42% vs. 0%; p < 0.0005), a Mirels score ≥9 (42% vs. 0%; p < 0.0005),
circumferential CI ≥30% (71% vs. 0%, p < 0.00001), CI ≥45 mm in height (67% vs. 0%, p < 0.00001) and CI in
thickness =100% (40% vs. 0%; p = 0.0008). In the multivariate analysis, circumferential CI ≥30% was the only
predictive parameter for fracture (p = 0.00035; OR = 62; CI 95%: 6.5-595). Overall survival was 91% and 40% at one
month and twelve months respectively.
Conclusions: Prophylactic primary fixation surgery should always be considered when the circumferential CI ≥30%.
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The aim of extracorporeal radiotherapy of the long
bones (RTLB) is to provide control of symptoms, des-
troy cancer cells in the treated area and prevent malig-
nant disease-related fractures. The analgesic potential of
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unless otherwise stated.overall response rates of 60%, including 23–24% com-
plete responses [1,2]. Bone radiotherapy is also a useful
means of halting tumor proliferation and then triggering
osteoblastic activity with osteoproliferation [3]. Bone
recalcification after RTLB has been observed in 70% of
cases, particularly in the fractionated group [3]; recalci-
fication commenced from the first month after RTLB
and peaked at three months [4]. Nonetheless, RTLB
does not entirely eliminate the risk of fracture [3], par-
ticularly in the three months immediately after radio-
therapy. A pathologic fracture may occur during thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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also considerably aggravate morbidity and mortality.
Prophylactic surgery (followed by RTLB) should be
discussed for patients with a high risk of fracture. RTLB
after surgery improves bone recalcification and guaran-
tees the stability of the new bone [5,6]. While the pri-
mary aim of fracture risk assessment is prevention, such
an assessment also reduces the risk of surgical over-
treatment in patients whose life expectancy is some-
times limited.
Numerous studies [1,7] have explored the risk of frac-
ture using radiographic images (standard x-rays) to de-
termine predictive factors. Analysis of the dimensions of
metastatic lesions, and especially any cortical involvement,
on standard x-rays alone remains insufficiently predictive
of the fracture risk. A three-dimensional CT study pro-
vides a more precise assessment of the risk of pathologic
fracture, but is not always carried out when the pain is
so great that radiotherapy is urgently required. CT scan-
based virtual simulation is therefore a valuable tool for
providing a precise analysis of tumor infiltration and
osteolysis.
The aim of our study was to use CT scan-based virtual
simulation to assess the risk of fracture and identify pre-
dictive factors with a view to offering prophylactic fix-
ation to those most at risk.
Materials and methods
Study design
This was a retrospective study conducted in a single
center. All patients requiring analgesic radiotherapy for
long bone metastasis were included. For 18 months, 47
patients were treated with RTLB (18 lung, 11 breast, 10
prostate, 8 other cancers). They had undergone a CT
scan-based virtual simulation prior to radiotherapy for a
long bone metastatic lesion and were enrolled between
September 2010 and February 2012. Two doctors ana-
lyzed the scans before irradiation. The impending frac-
tures were then monitored and the correlation between
bone scan parameters and fracture occurrence was ana-
lyzed. All patients were seen for follow-up and treated
solely at our center. Follow-up ended in June 2012: each
patient had been monitored for a minimum of four
months in order to screen for post-RTLB fractures. Recal-
cification commenced from the first month after RTLB
and peaked at three months [4]; therefore, the fracture risk
was considered low after the third month.
Data collected
Using medical records, we recorded each patient's me-
dical history, primary cancer histological type with sta-
ging, RTLB procedures, fractures and disease course.
The target lesion was documented with standard x-rays,
bone scintigraphy or a diagnostic CT scan.The virtual simulation was carried out using a 16-slice
GE scanner with an 80 cm ring no more than three
weeks prior to the start of radiotherapy. The total dose,
fractionation, X-ray energy and interval between sessions
varied depending on the general condition of the patient,
the intensity of pain experienced lying on the scanner
bed and technical constraints.
Two doctors (a radiotherapist and an oncologist) sys-
tematically analyzed several parameters that are known
to be risk factors for pathologic fractures from previous
publications [8-24]: the type and appearance of a me-
tastasis, the mean dimensions of the lesion and the cor-
tical involvement (CI) (craniocaudal, circumferential and
thickness [Figure 1]):
– Type of metastasis: a lesion was considered to be
"well defined" if its external margins were
identifiable in all three spatial planes and "diffuse" if
its margins were difficult to identify in the three-
dimensional analysis because of an infiltrative
appearance.
– - Appearance of metastasis: lesions were divided
into five categories. They could be "normal" (normal
appearance of the bone on the scan), "osteolytic"
(a primarily lytic lesion with a decrease in bone
density), “osteoblastic” (a mainly blastic lesion with
an increase in bone density), "mixed" (both lytic and
blastic features) or "moth-eaten" (homogeneous
"chewed", infiltrated appearance).
– The mean dimensions of the metastatic lesion were
also measured (height, diameter in the transverse
plane and CI). Lesion height (mm) was assessed by
measuring the difference between the outermost
transverse slice and the innermost slice on which
the lesion could be seen, and then multiplying this
difference by the thickness of the CT slices.
"Diameter 1" (mm) was the length of the widest axis
of the metastatic lesion in the transverse plane.
"Diameter 2" (mm) was the largest dimension
measured perpendicular to "Diameter 1" in the
transverse plane. Circumference was measured in
the area considered to be most at risk of fracture by
both observers. Circumference perimeter was the
measurement of the external perimeter of the
cortical bone (mm) in the most at-risk area.
– Cortical thickness (mm) was the measurement of
the thickness of the cortex considered to be normal
in the most at-risk area.
– Craniocaudal cortical lysis (mm) was the
measurement of the maximum CI height in the
craniocaudal plane. The 30 mm threshold
involvement was always recorded since this is the
threshold predictive of pathological fracture
according to several authors [11,22,23].
Figure 1 Diagrammatic slice of a bone diaphysis.
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measurement of the diseased cortex perimeter in the
most at-risk area. The circumferential lysis percentage
was systematically determined by calculating the ratio
of circumferential cortical lysis to the circumferential
perimeter of the bone. The threshold involvement of
50% was always recorded since this is the threshold
predictive of pathologic fracture according to several
authors [9,10,15-17,21-23].– Cortical thickness lysis (mm) was the measurement
of the maximum thickness of cortical lysis in the
at-risk area. The percentage of cortical lysis thickness
was always determined.
– The Mirels score takes into account anatomical
location, extent of cortical lysis, appearance of the
lesion and pain intensity [21] and was calculated for
each metastatic lesion. A Mirels score of nine or
more was found to be predictive of fracture.
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the lesion with the highest risk of fracture was
measured.Statistical analysis
The statistical analysis was conducted using the Chi2 test
and means comparison test. The performance character-
istics of the craniocaudal and circumferential cortical
lysis thresholds were analyzed using the ROC curve.
Logistic regression generalized linear modeling was
used for the multivariate analysis.
The overall survival and fracture incidence curves were
calculated using the Kaplan–Meier method. A Log-Rank
test was used to compare the survival curves.
The value of p was considered significant when <0.05.
Results
Between September 2010 and February 2012, 37 patients
with 47 lesions (28 femoral, 17 humeral and two tibial)
underwent analgesic radiotherapy for long bone metasta-
sis. The patients had been monitored for a minimum of
four months. The male gender ratio was 0.59 and the
mean age was 62.8 years (33–93). Cancer staging was I–II
for 56.8% and II–III for 43.2%. The primary cancers were
lung (35.1%), prostate (27%), breast (16.3%) and others
(21.6%). There were 32 adenocarcinomas, two squamous-
cell cancers and three other types. At the moment their
painful long bone metastasis was discovered, 18 patients
had been receiving treatment with bisphosphonates and
25 with chemotherapy. Surgery was not initially per-
formed for a variety of reasons, including poor general
patient health, increase in pain refractory to medical
treatment requiring urgent radiotherapy and low risk of
impending fracture. Twenty-two [22] of the 47 lesions
received a single dose (7 to 8 Gy). The 25 other lesions
received 15 to 30 Gy in three to ten sessions over three
to 19 days. The radiation dose was delivered through
hard X-ray energy (5.5 to 18 MV).Figure 2 Probability of fracture—free survival following RTLB (KaplanTen of the 47 radiated lesions fractured during or after
RTLB. When overall survival is taken into account, the
incidence of fractures was 20% one month after RTLB
and 25.9% at the end of the study. Two fractures oc-
curred during RTLB, and another seven occurred in the
first thirty days. The last fracture occurred at 6.6 months
(Figure 2).
Factors predictive of fracture
In the univariate analysis (Table 1), the primary cancer
type, histological type, prior treatments (chemotherapy,
hormone therapy, targeted therapies and radiotherapy),
symptomatic treatments (bisphosphonates and cortico-
steroids) were not predictive of fractures. We found no
statistically significant difference in anatomical lesion lo-
cation (upper, middle or lower third; p = 0.85), bone type
(femur, humerus, tibia), existence of local predisposing
factors or radiation treatment schedule. There was no
correlation between radiotherapy schedule and bone
fracture: the radiotherapy procedures were the same in
both groups, with or without fractures (Table 2).
The risk factors for impending fracture were as follows:
an osteolytic (39% vs. 10%; p = 0.02) and diffuse appear-
ance (42% vs. 0%; p < 0.0005), circumferential CI ≥50%
(80% vs. 5%, p < 0.00001) and ≥30% (71% vs. 0%, p <
0.00001), height of involvement ≥30 mm (48% vs. 0%, p <
0.00001) and ≥45 mm (67% vs. 0%, p < 0.00001) and cor-
tical thickness =100% (38% vs. 0%; p = 0.0008). A Mirels
score ≥9 (42% vs. 0%; p < 0.0005) was also predictive of
fracture.
The craniocaudal and circumferential involvement
thresholds with the greatest sensitivity and specificity in
the study population were ≥45 mm for craniocaudal in-
volvement and ≥30% for circumferential involvement
(Figure 3).
In the multivariate analysis, only circumferential in-
volvement ≥30% was predictive of fracture (p =0.00035;
OR =62; CI 95% = [6.45 – 595]).—Meier).
Table 1 Comparison of characteristics, group with fracture versus group without fracture (Chi 2 test, comparison of
means) a) Clinical parameters
Total (%) Fractures (%) Without fractures (%)
Number of patients 37 10 27
Number of lesions radiated 47 10 37
Age p = 0.16
Mean (years) 62.8 65.3 62.2
Age range (years) 33 - 93 33 - 87 33 - 93
Gender NS
Men 27 (57.5) 4 (14.8) 23 (85.2)
Women 20 (42.5) 6 (30) 14 (70)
Primary cancer NS
Lung 18 (38.3) 4 (22) 14 (78)
Breast 11 (23.4) 3 (27) 8 (73)
Prostate 10 (21.3) --- 10 (100) p = 0.08
Other 8 (17.0) 3 (37.5) 5 (62.5)
Corticosteroids NS
< 1 month 1 (2.1) 1 (100) ---
> 1 month and < 6 months 2 (4.2) 1 (50) 1 (50)
> 6 months 0 --- ---
No 42 (89.5) 8 (19) 34 (81)
NA 2 (4.2) --- 2 (100)
Biphosphonates NS
Yes 21 (44.7) 4 (19) 17 (81)
No 21 (44.7) 4 (19) 17 (81)
NA 5 (10.6) 2 (40) 3 (60)
Chemotherapy ongoing p = 0.03
Yes 34 (72.3) 10 (29) 24 (71)
No 13 (27.7) --- 13 (100)
Long bone NS
Femur 28 (59.6) 7 (25) 21(75)
Humerus 17 (36.2) 3 (18) 14(78)
Tibia 2 (4.2) --- 2 (100)
Locoregional history NS
Fracture 2 (4.2) 1 (50) 1 (50)
Osteoarthritis 5 (10.5) --- 5 (100)
No 40 (85.1) 9 (23) 31 (77)
Contralateral prosthesis 4 (8.5) --- 4 (100) NS
Pain intensification NS
Yes 42 (89.4) 10 (24) 32 (76)
No 5 (10.6) --- 5 (100)
a) Radiological parameters
Number of lesions radiated 47 10 37
Localization NS
Upper third 43 (91.5) 9 (21) 34 (79)
Lower third 4 (8.5) 1 (25) 3 (75)
Tatar et al. Radiation Oncology 2014, 9:227 Page 5 of 10
http://www.ro-journal.com/content/9/1/227
Table 1 Comparison of characteristics, group with fracture versus group without fracture (Chi 2 test, comparison of
means) a) Clinical parameters (Continued)
Type of metastatic spread
Well defined 23 (49.0) --- 23 (100) p = 0.0005
Diffuse 24 (51.0) 10 (42) 14 (58)
Appearance of the metastatic lesion
Normal 2 (4.2) --- 2 (100)
p = 0.02
Osteolytic 18 (38.3) 7 (39) 11 (61)
Mixed 15 (31.9) 3 (20) 12 (80)
Osteoblastic 11 (23.5) --- 11 (100)
Moth---eaten 1 (2.1) --- 1 (100)
Mean dimensions (mm)
Height 59.8 80.07 46.1
CI 95% (40.5; 79.1) (50.37; 109.8) (33.3; 58.9) p < 0.01
Diameter 1 32.2 48.5 27.6
CI 95% (26.8; 37.5) (41.8; 55.1) (22.7; 32.6) p = 0.01
Diameter 2 22.9 34.2 19.8
CI 95% (18.6; 27.3) (29.5; 38.8) (15.3; 24.3) p = 0.01
Circumferential perimeter 142.6 133.1 145.2 p = 0.15
CI 95% (129.9; 155.3) (127.1; 139.1) (130.3; 160.1)
Cortical thickness 3.5 3.3 3.6 p = 0.27
CI 95% (3.1; 3.9) (3.2; 3.4) (3.1; 4.0)
Craniocaudal cortical lysis p < 0.0001
Mean (mm) 45.2 103.0 28.6
CI 95% (25.3; 65.0) (85.6; 120.4) (14.7; 42.6)
Cortical lysis threshold
No 16(34.0) --- 16 (100)
< 30 mm 10 (21.3) --- 10 (100)
≥ 30 mm 21 (44.7) 10 (47.6) 11 (52.4)
Circumferential cortical lysis p < 0.0001
Mean (mm) 32.3 78.6 19.8
CI 95% (22.3; 42.3) (74.5; 82.6) (11.6; 28.1)
Cortical lysis (%)
No 16 (34.0) --- 16 (100)
< 50% 21 (44.7) 2 (9.5) 19 (90.5)
≥ 50% 10 (21.3) 8 (80) 2 (20)
Cortical lysis in thickness p = 0.0018
Mean (mm) 2.2 3.3 2.0
CI 95% (1.6; 2.9) (3.2; 3.4) (1.2; 2.7)
Cortical lysis (%)
No 16 (34.0) --- 16 (100)
0 – 99% 5 (10.7) --- 5 (100)
100% 26 (55.3) 10 (38.5) 16 (61.5)
Mirels score P = 0.0005
≤ 7 14 (29.8) --- 14 (100)
= 8 9 (19.1) --- 9 (100)
≥ 9 24 (51.1) 10 (42) 14 (58)
CI: confidence Interval; NA: not applicable; NS: not significant.
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Table 2 Comparison of fractionation type, group with
fracture versus group without fracture
N (%) Fractures (%) Without
fractures (%)
Number of lesions radiated 47 10 37
Dose received
Single fraction 22 (46.8) 5 (22.7) 17 (77.3)
7 Gy 3 (6.4) --- 3 (100)
8 Gy 19 (40.4) 5 (26.3) 14 (73.7)
Multiple fractions 25 (53.2) 5 (20) 20 (80)
15 Gy 1 (2.1) --- 1 (100)
20 Gy 13 (27.7) 3 (23.1) 10 (76.9)
25 Gy 3 (6.4) --- 3 (100)
30 Gy 8 (17.0) 2 (25) 6 (75)
Figure 3 ROC curve. A) Performance of the craniocaudal cortical lysis thre
less than 42.5 mm. 45 mm threshold: sensitivity = 100%, specificity = 85.7%,
B) Performance of the circumferential cortical involvement threshold. No ri
27%. 30% threshold: sensitivity = 100%, specificity = 89%, positive predictive
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The mean follow-up was 5.95 months (0.43–20.27 months)
for the 37-patient study population. No patients were lost
to follow-up.
Overall survival was 91%, 55% and 40% at one month,
six months and one year respectively (Figure 4). Overall
survival was significantly lower in the patients presenting
with fractures (p = 0.014).Discussion
Our study showed that more than 25% of patients un-
dergoing radiotherapy for metastases presented with a
fracture. In the multivariate analysis, the only factor pre-
dictive of fractures identified during the CT-scan-based
virtual simulation study was circumferential a CI ≥30%.shold. No risk of fracture if the craniocaudal cortical involvement is
positive predictive value = 66.7%, negative predictive value = 100%.
sk of fracture if the circumferential cortical involvement is less than
value = 71%, negative predictive value = 100%.
Figure 4 Overall survival after RTLB as a function of fracture incidence. Curve 1: with fracture. Curve 2: without fracture Overall survival
curve, Kaplan–Meier; Log–‐Rank, p = 0.014.
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tures using radiographic images (standard X-rays) to de-
termine predictive factors. In general, high impending
fracture risk lesions are lytic [8-17], proximal [10,18,19],
large (>25 mm) [8-10] and femoral (Harrington criteria,
[10,25]). They trigger increasing pain [8-11,13-15,17,20,21],
involve more than 50% of the cortex circumference
[9,10,15-17,21-23] with craniocaudal cortex involvement
of over 30 mm [11,22-24] and a Mirels score of ≥9 [21].
As in other studies, we found that the other radiolo-
gical parameters predictive of fracture were a lytic, diffuse,
poorly circumscribed appearance and cortical involvement
(30% circumferential, 45 mm height and 100% thickness).
In our study, ≥30 mm femoral craniocaudal cortical in-
volvement was a significant predictor of fracture risk in
the univariate analysis, but this consideration could have
led to 14 unnecessary surgical procedures (37.8% false
positive rate).
In our series, a composite Mirels score of ≥9 was also
predictive of fracture. However, while this score has
the advantage of being very sensitive, it lacks specifi-
city [7,23,24]. Therefore, in our study this score was ≥9 in
100% of the fracture cases, but there were 14 false posi-
tives (37.8%). The three-dimensional study clearly pro-
vides a more precise assessment of the risk of pathologic
fracture. Measuring circumferential cortical involvement
enhances this assessment: primary surgical fixation should
be considered in patients with circumferential cortical in-
volvement ≥30%.
Our study was representative and comparable with
those reported in other series in the literature in terms
of age, gender, primary cancer type, performance statusand fracture rates [6,15,24,26-28]. In our series, radio-
therapy procedures and fractionation did not affect the
fracture incidence and the data in the literature are dis-
cordant on this point [26,28]. Furthermore, in our popu-
lation, bisphosphonate administration did not influence
the risk of bone fractures.
Nevertheless, our study has several limitations:
– It is retrospective in design and our population was
very small. However, all the patients treated with
RTLB were enrolled and none were lost to follow-
up, which represents a real-life experience.
– The four-month follow-up period could also be seen
as a limitation of our study. However, 90% of the
fractures occurred in the month following RTLB and
it has been shown that bone recalcification is
obtained three months after RTLB, after which time
the risk of fractures is very low [4].
– While our scan images were read by a radiotherapist
and an oncologist rather than a radiologist, these are
the healthcare professionals who are required to
assess fracture risk in patients with painful bone
metastases on a daily basis. Our patients were
oriented directly for urgent analgesic radiation and a
CT scan was performed promptly for the virtual
simulation (without evaluation by a radiologist). At
the same time, we recorded bone scan parameters
for this study.
– Due to the retrospective nature of the study, some
risk factors for fracture could not be included, such
as assist devices, weight-bearing status, bone density
status, smoking status and osteoporosis comorbidity.
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cluding a much larger series of patients, since it is im-
portant to precisely establish when prophylactic fixation
is required to reduce morbidity and mortality [5,6,10,15].
The development of an instrument that identifies pa-
tients who have a relatively high risk of developing such
a fracture and therefore should be considered candidates
for surgical stabilization is helpful. This strategy could
optimize the management of fragile metastatic patients.
Elective surgery in patients in good general health is sim-
pler and less risky than an emergency procedure, with
more rapid relief of pain and recovery of mobility [29,30].
Surgical overtreatment also unnecessarily increases mor-
bidity (e.g., hospitalization, general anesthetics and com-
plications arising from a forced supine position) in
patients whose life expectancy is limited. The appropriate
management of palliative patients and cost-effective pro-
active approaches may offer more clinical benefit and
value for carefully selected patients.Conclusions
This study analyzes the risk of fractures following radi-
ation for bone metastasis and attempts to determine
which patient population would benefit from prophylac-
tic surgery. Circumferential cortical involvement is easy
to measure and should be systematic during CT scan-
based virtual simulation prior to radiotherapy.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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